NEW YORK \u2013 February 25, 2026<\/p>\n
Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer\u2019s disease, Parkinson\u2019s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2nd, 2026 at 11:50 AM (ET).<\/p>\n
A live audio webcast will be accessible through the Investors section of the Company\u2019s website at www.anavex.com<\/a>. An archived edition of the session will be available later that day.<\/p>\n About Anavex Life Sciences Corp.<\/p>\n Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer\u2019s disease, Parkinson\u2019s disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex\u2019s lead drug candidate, ANAVEX\u00ae2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b\/3 clinical trial for Alzheimer\u2019s disease, a Phase 2 proof-of-concept study in Parkinson\u2019s disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2\/3 study in pediatric patients with Rett syndrome. ANAVEX\u00ae2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and\/or reverse the course of Alzheimer\u2019s disease. ANAVEX\u00ae2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson\u2019s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX\u00ae2-73 for the treatment of Parkinson\u2019s disease. We believe that ANAVEX\u00ae3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer\u2019s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX\u00ae3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com<\/a>. You can also connect with the Company on Twitter,<\/a> Facebook<\/a>, Instagram<\/a>, and LinkedIn<\/a>.<\/p>\n Forward-Looking Statements<\/p>\n Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.<\/p>\n \u00a0<\/p>\n For Further Information:<\/p>\n Anavex Life Sciences Corp. Investors:<\/p>\n Andrew J. Barwicki
\nResearch & Business Development
\nToll-free: 1-844-689-3939
\nEmail: info@anavex.com<\/a><\/p>\n
\nInvestor Relations
\nTel: 516-662-9461
\nEmail: andrew@barwicki.com<\/a>